Business Context and Reporting Period
Company: Pacific Biosciences of California, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 5, 2012
Event: Entry into a Material Definitive Agreement for a Controlled Equity Offering.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The financial data provided relates solely to the terms of a new equity financing agreement:
- Aggregate Offering Price: Up to $30.0 million.
- Commission to Sales Agent: 3.0% of the gross sales price per share sold.
- Legal Fee Reimbursement Cap: $50,000 in the aggregate.
Material Changes
On October 5, 2012, the Company entered into a Sales Agreement with Cantor Fitzgerald & Co. This agreement authorizes the Company to offer and sell shares of its common stock through an "at-the-market" offering. This represents a new mechanism for raising capital compared to prior periods, allowing for sales on The NASDAQ Global Select Market or through privately negotiated transactions.
Guidance, Outlook, and Management Commentary
Use of Proceeds: The Company intends to use the net proceeds for general corporate purposes, including capital expenditures and working capital. A portion may also be used to acquire or invest in complementary businesses, technologies, product candidates, or other intellectual property.
Offering Terms: The Company is not obligated to make any sales under the agreement. The offering will terminate upon the sale of all shares or the termination of the agreement by either party.
Risks and Contingencies: The filing notes that the report does not constitute an offer to sell in any state where such an offer would be unlawful prior to registration or qualification.
Important Facts for Investor Verification
- Verify the current share price and potential dilution impact of selling up to $30.0 million in equity.
- Confirm the status of the previously filed Registration Statement on Form S-3 (File No. 333-180533) referenced for the issuance of shares.
- Monitor future 8-K filings or quarterly reports to determine the actual volume of shares sold and the specific allocation of proceeds between working capital and acquisitions.
- Review the full text of the Controlled Equity Offering Sales Agreement (Exhibit 10.1) for specific termination rights and price limitations.